Fondaparinux sodium bulk supplier for pharma manufacturers

Fondaparinux Sodium Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, 10 mg/0.8 mL

Reference Brands: Arixtra (USA)

Fondaparinux is a synthetic anticoagulant that inhibits factor Xa, an essential enzyme in the blood clotting process. It is used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE) and to prevent blood clots after major orthopedic or abdominal surgery.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Fondaparinux Sodium — third party manufacturing & bulk supply

Fondaparinux Sodium is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Fondaparinux Sodium is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Fondaparinux Sodium listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Fondaparinux Sodium →

Back to Listing

Frequently Asked Questions

Fondaparinux sodium is used to prevent and treat blood clots in conditions such as deep vein thrombosis and pulmonary embolism, particularly after orthopedic or abdominal surgery.

Fondaparinux sodium is made from a synthetic pentasaccharide that selectively inhibits activated Factor Xa, preventing clot formation.

Trade names include Arixtra and Idraparinux (investigational).

Fondaparinux sodium is manufactured by Aspen Pharmacare, Mylan, and originally developed by GlaxoSmithKline under the brand name Arixtra.

The generic name is Fondaparinux sodium.

The brand name is Arixtra.

Fondaparinux sodium is manufactured in countries such as the United States, India, and the United Kingdom by several pharmaceutical companies for both hospital and retail use.